Pfizer Independent Medical Education RFP
Emerging Science in the Management ofAcute Myeloid Leukemia
Competitive Grant Program – Pfizer Internal Review ProcessOverview
The purpose of this RFP is to support programs that will provide
education to healthcare professionals surrounding advances in thetreatment of AML for patients not fit for intensive chemotherapy, inorder to help clinicians make evidence-based treatment decisions.

Geographic Scope
GlobalProject Types and Area of Interest
Educational formats including independent conference highlights,
educational meeting recaps, and virtual learning options will beprioritized.
The education should focus on emerging evidence in AML.

Key Milestones• Application submission deadline: September 7, 2023
• Anticipated decision notification date: October 13, 2023
• Anticipated project start date: December 1, 2023

Funding Range and Project Length
Funding requests up to $150,000 will be considered. Project duration
can run up to 15 months.

I. Eligibility
Geographic Scope:•GlobalApplicant Eligibility Criteria
•
•••
•
•

•

Only organizations are eligible to receive grants, not individuals or medical practice groups.
The following may apply: medical, nursing, allied health, and/or pharmacy professional schools;
healthcare institutions (both large and small); professional associations and medical societies;
medical education companies; and other entities with a mission related to healthcare professional
education and/or healthcare improvement.
If the project involves multiple departments within an institution and/or between different institutions /organizations / associations. All institutions must have a relevant role and the requesting organizationmust have a key role in the project.
The applicant must be the project/program lead or an authorized designee of such individual (e.g.,
project/program lead’s grant coordinator).
The project/program lead must be an employee or independent contractor of the requestingorganization.
Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We
strongly recommend that applicants confirm this with their organization or institution prior to submitting
an application. Grants awarded to organizations that are subsequently found to be unable to accept
funding directly from Pfizer Inc. may be subject to rescission.
For projects offering continuing education credit, the requesting organization must be accredited.

II. Requirements
Date RFP Issued:•July 27, 2023

Clinical Area:•Acute Myeloid Leukemia

General Area of Interest for this RFP:
•Projects that will be considered for Pfizer support will focus on education surrounding emerging
evidence in acute myeloid leukemia including:• Improve knowledge of the role of CD47 targeting agents in the treatment of AML in patients who
are not candidates for intensive chemotherapy• Increase knowledge of unmet needs when treating patients with AML unsuitable for intensivechemotherapy• Increase understanding of the mechanism of action and the scientific rationale for anti-CD47
agents as potential treatment options for AML• Increase awareness of emerging data and key differences between CD47 targeting agents indevelopment
Educational formats including independent conference highlights from the American Society ofHematology and other recent congresses, educational meeting recaps, and virtual learning options
will be prioritized.
It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeuticor diagnostic agents will not be considered.

2Target Audience:•Hematologists/Oncologists and other healthcare providers involved in the treatment of patients withAML

Expected Approximate Monetary Range of Grant Applications:••Individual projects requesting up to $150,000 will be considered. The estimated total available budget
related to this RFP is $300,000.
Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy),
and indirect costs.

Key Dates:••••

RFP release date: July 27, 2023
Grant Application due date: September 7, 2023
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
Anticipated Grant Award Notification Date: October 13, 2023
Grants will be distributed following a fully executed agreement.
Anticipated Project Start and End Dates: December 2023 to March 2025.

How to Submit:
Note: Please read this section carefully since applications submitted not following these instructions will
not be accepted and will be cancelled.
• Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create
your password”. [Note: there are individual portals for each grant application type. Please be sure touse the URL above.]• Click the “Start A New Knowledge Gap Application" button.
• In the application:• For the question “What type of request are you submitting?” select Response to a Request forProposal (RFP)• For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive
Grant Program?” select Yes• Select the following Competitive Grant Program Name: 2023 ONC G AML Emerging ScienceIME• Select the following Primary Area of Interest: Oncology-hematologic• Requirements for submission:
Complete all required sections of the online application and upload your project proposal (seeAppendix) in the General RFP Submission field.
• If you encounter any technical difficulties with the website, please click the “Technical Questions” linkat the bottom of the page.
• Please click here for a checklist to refer to PRIOR to submitting your application.
IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:•If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda
Kaczerski (Amanda.Kaczerski@pfizer.com), with the subject line “2023 ONC G AML Emerging
Science IME.”

3

Grant Agreements:••••

If your grant is approved, your institution will be required to enter into a written grant agreement withPfizer. Please click here to view the core terms of the agreement.
Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed
unless a genuine conflict exists as between applicable law and the terms of the relevant grantagreement. Applicant is encouraged to share the core terms with counsel for approval prior tosubmitting an application.
Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal,
payment of grant funding may only be paid to the grantee organization.
This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process:•Grant requests received in response to a general RFP are reviewed by Pfizer to make final grantdecisions.

Mechanism by which Applicants will be Notified:••

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review period.

References:•Bibliography of relevant references.

About Pfizer Global Medical Grants
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g.,research, quality improvement, or education) to improve patient outcomes in areas of unmet medical needthat are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) thatprovides detail regarding a general area of interest, sets timelines for review and approval, and uses aninternal Pfizer review process to make final grant decisions. Organizations are invited to submit an application
addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is
responsible for the design, implementation, and conduct of the independent initiative supported by
the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of theindependent education program.

4

Appendix
General RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals
should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit
exclusive of references. When uploading your Project Proposal please ensure it addresses the following
sections:Goals and Objectives••

Briefly state the overall goal of the project.
List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project•

Include a description of your organization’s needs assessment for this proposed project which may
include a quantitative baseline data summary, initial metrics, or a project starting point (please cite dataon gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience•

Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit
from the project outcomes. Describe the overall population size as well as the size of your sample
population.

Project Design and Methods•

Describe the planned project, the educational approach, and the way the planned methods address theestablished need.

Innovation•

Explain what measures you have taken to assure that this project is original and does not duplicate otherprojects or materials already developed. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes•

In terms of the metrics used for the needs assessment, describe how your organization will determine if
the gap was addressed for the target group. Identify the sources of data your organization anticipatesusing to make the determination. Describe how your organization is expected to collect and analyze thedata. Explain the method used to control for other factors outside this project (e.g., use of a control groupor comparison with baseline data). Quantify the amount of change expected from this project in terms thetarget audience. Describe how your organization will determine if the target audience was fully engaged
in the project.

Dissemination Plan•

Describe how the project may have extended benefit beyond the grant. Will the teaching materials bemade available to others to use? Will there be tools or resources that are made publicly available
beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline•

Provide an anticipated timeline for your project including project start/end dates.

5Additional Information•

If there is any additional information you feel Pfizer should be aware of concerning the importance of thisproject, please summarize here.

Organization Detail•

Describe the attributes of the institutions / organizations / associations that will support and facilitate theexecution of the project and the leadership of the proposed project. Articulate the specific role of eachpartner in the proposed project.

Budget Detail••Please include a budget narrative that describes in greater detail the line items specified in the budget
submitted within the application.
While estimating your budget please keep the following items in mind:• Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic
assets (prescription or non-prescription).
• Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.
Please click here for details.

6